Reviewing Dyadic International (NASDAQ:DYAI) & Enzon Pharmaceuticals (OTCMKTS:ENZN)

Dyadic International (NASDAQ:DYAI) and Enzon Pharmaceuticals (OTCMKTS:ENZN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Dyadic International and Enzon Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	0	0	1	0	3.00
Enzon Pharmaceuticals	0	0	0	0	N/A

Dyadic International presently has a consensus target price of $6.00, suggesting a potential upside of 259.28%. Given Dyadic International’s higher possible upside, equities analysts clearly believe Dyadic International is more favorable than Enzon Pharmaceuticals.

Earnings & Valuation

This table compares Dyadic International and Enzon Pharmaceuticals’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$2.93 million	16.42	-$9.73 million	($0.23)	-7.26
Enzon Pharmaceuticals	$30,000.00	N/A	$1.37 million	$0.01	9.46

Enzon Pharmaceuticals has lower revenue, but higher earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Enzon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

28.0% of Dyadic International shares are held by institutional investors. 27.3% of Dyadic International shares are held by insiders. Comparatively, 0.3% of Enzon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Dyadic International and Enzon Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyadic International	-232.38%	-71.31%	-58.64%
Enzon Pharmaceuticals	N/A	46.47%	2.92%

Volatility and Risk

Dyadic International has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Enzon Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.

About Dyadic International

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design,Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.